Patents Assigned to Janssen Pharmaceuticals, Inc.
-
Patent number: 11602599Abstract: An accessory for an injection device having a needle cap. The accessory comprises a body portion comprising a recess adapted to receive the injection device and a cover coupled to the body portion. The cover is pivotally moveable between an open position in which the recess is exposed to receive the injection device, and a closed position in which the cover at least partially closes the recess to hold the injection device in the body portion. The accessory further comprises a cap remover comprising a grip adapted to hold the needle cap. The cap remover is moveable with respect to the body portion.Type: GrantFiled: December 17, 2019Date of Patent: March 14, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: James D. McLusky, Nick Foley, Gavin F. McDougall, Roy A. Crerar, James N. Mower
-
Patent number: 11591377Abstract: Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described. The methods include administering a liposomal priming composition containing tau peptides, preferably phosphorylated tau peptides, and a conjugate boosting composition containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier.Type: GrantFiled: April 23, 2020Date of Patent: February 28, 2023Assignees: Janssen Pharmaceuticals, Inc., AC Immune SAInventors: Elizabeth Anne Ramsburg, Donata De Marco, Chakkumkal Anish, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, David Hickman, Nicolas Piot, Saroj Raj Ghimire
-
Patent number: 11555205Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.Type: GrantFiled: December 4, 2019Date of Patent: January 17, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico
-
Publication number: 20220409583Abstract: The present invention relates to the use of substituted indole derivatives and substituted indoline derivatives in the manufacture of a medicament for the treatment of dengue disease in an individual infected by dengue virus or the prevention of dengue disease in an individual at risk of being infected by Dengue virus. The invention further provides a method for the treatment or the prevention of dengue in an individual at risk of being infected by Dengue virus.Type: ApplicationFiled: November 13, 2020Publication date: December 29, 2022Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Olivia Gabriella M. GOETHALS, Bart Rudolf Romanie KESTELEYN, Bart Henri Theresia STOOPS, Jean-François BONFANTI, Tim Hugo Maria JONCKERS, Marnix VAN LOOCK, Suzanne KAPTEIN, Johan NEYTS
-
Patent number: 11529405Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.Type: GrantFiled: February 4, 2021Date of Patent: December 20, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: Eszter Nagy, Gäbor Nagy, Valéria Szijárto, Zóltan Magyarics, Irina Mirkina, Luis Gauchalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
-
Patent number: 11525000Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.Type: GrantFiled: April 14, 2017Date of Patent: December 13, 2022Assignees: IMMUNEXT, INC., JANSSEN PHARMACEUTICALS, INC.Inventors: Michael Molloy, Jay Rothstein, Dov Pechenick, Linda Snyder, Gordon Powers
-
Patent number: 11498944Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: GrantFiled: January 30, 2021Date of Patent: November 15, 2022Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
-
Patent number: 11491220Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).Type: GrantFiled: March 18, 2020Date of Patent: November 8, 2022Assignees: Janssen Pharmaceuticals, Inc.Inventors: Jeroen Geurtsen, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Jan Theunis Poolman, Kellen Cristhina Fae, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11484582Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: GrantFiled: February 4, 2020Date of Patent: November 1, 2022Assignees: Janssen Pharmaceuticals, Inc.Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
-
Publication number: 20220340522Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: ApplicationFiled: June 16, 2022Publication date: October 27, 2022Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Jérôme Michel Claude Fortin, Guillaume Jean Maurice Mercey, Pierre Jean-Marie Bernard Raboisson
-
Patent number: 11446446Abstract: An accessory for an injection device having a needle cap. The accessory comprises a body portion comprising a recess adapted to receive the injection device and a cover coupled to the body portion. The cover is pivotally moveable between an open position in which the recess is exposed to receive the injection device, and a closed position in which the cover at least partially closes the recess to hold the injection device in the body portion. The accessory further comprises a cap remover comprising a grip, the cap remover having an expanded configuration in which the needle cap can pass between the grip, and a constricted configuration in which the grip holds the needle cap to at least partially remove the needle cap from the injection device.Type: GrantFiled: December 17, 2019Date of Patent: September 20, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: James D. McLusky, Nick Foley, Gavin F. McDougall, Roy A. Crerar, James N. Mower
-
Patent number: 11446370Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: March 18, 2020Date of Patent: September 20, 2022Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11421003Abstract: Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.Type: GrantFiled: January 15, 2021Date of Patent: August 23, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: Jan Grijpstra, Marleen Eveline Weerdenburg, Jeroen Geurtsen, Cristhina Kellen Fae, Jakob Louris Feitsma
-
Patent number: 11407715Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: May 18, 2018Date of Patent: August 9, 2022Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Jérôme Michel Claude Fortin, Guillaume Jean Maurice Mercey, Pierre Jean-Marie Bernard Raboisson
-
Publication number: 20220227819Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.Type: ApplicationFiled: December 21, 2021Publication date: July 21, 2022Applicants: The University of Chicago, Janssen Pharmaceuticals, Inc.Inventors: Dominique Missiakas, Olaf Schneewind, Carla Emolo, Lena Thomer, Molly McAdow, Jeroen Geurtsen, Mark De Been
-
Patent number: 11384122Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: GrantFiled: July 28, 2021Date of Patent: July 12, 2022Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel le Gars, Jerald C. Sadoff
-
Publication number: 20220193085Abstract: Methods of thromboprophylaxis using rivaroxaban is provided for children with congenital heart disease post-Fontan procedure.Type: ApplicationFiled: December 16, 2021Publication date: June 23, 2022Applicants: JANSSEN PHARMACEUTICALS, INC., BAYER PHARMA ATKIENGESELLSCHAFTInventors: CHRISTOPHER NESSEL, Stefan Willmann, Dagmar Kubitza, Roger M. Mills, Catherine Vanden Boom, Elliot Barnathan, Liza Miriam Pina
-
Patent number: 11364310Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecules of interest. The disclosure relates to nucleic acid constructs, such as expression vectors, containing a modified replicon RNA which includes a modified 5?-unstranslated region (5?-UTR) and, optionally, at least some of its original viral sequence encoding structural proteins having been deleted. Also disclosed are methods for producing polypeptides of interest.Type: GrantFiled: October 3, 2017Date of Patent: June 21, 2022Assignee: JANSSEN PHARMACEUTICALS, INC.Inventor: Kurt Iver Kamrud
-
Patent number: D956215Type: GrantFiled: January 14, 2022Date of Patent: June 28, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: Peter Krulevitch, Michael Cannamela, Yuji Ikeda, Nick Foley, James McLusky, Jimmy Mower, Scott Martin, James Glencross
-
Patent number: D958330Type: GrantFiled: June 14, 2019Date of Patent: July 19, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: James McLusky, Nick Foley, Gavin Fraser McDougall, Roy Andrew Crerar, Jimmy Mower